Xencor

Xeris Pharmaceuticals, now known as Xeris Biopharma Holdings, Inc., is a biopharmaceutical company based in Chicago, Illinois. Founded in 2005 by Steve Prestrelski and John Kinzell, Xeris focuses on developing and commercializing advanced therapeutic products, particularly through innovative drug delivery technologies. The company aims to enhance patient convenience and treatment efficacy with its ready-to-use injectable formulations. Xeris's product portfolio includes Gvoke, an FDA-approved glucagon injection for treating severe hypoglycemia in diabetes patients, and therapies for primary periodic paralysis and Cushing's syndrome. The company expanded its offerings through the acquisition of Strongbridge Biopharma in 2020, which added rare disease products to its lineup. Xeris holds 40 patents and has proprietary formulation technology for sustained-release therapeutic compositions. The company went public in 2018 and continues to pursue strategic collaborations to advance its innovative therapies.

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).